mRNA synthesis services: specifying ivt mrna synthesis by capping, modified nucleotides and purification, and the analytics that decide whether the material performs

The specification that decides performance

1. Template and sequence elements. The template's promoter, the untranslated regions and the poly-A tail all affect expression and stability, and the tail can be encoded in the template or added enzymatically with different consequences for length uniformity. Specify these rather than accepting a default.
2. Capping route. Co-transcriptional capping with a cap analogue is a single step; enzymatic capping after transcription is a second reaction with generally higher capping efficiency. Ask which is used and what capping efficiency is measured and reported, because uncapped RNA is both non-productive and immunostimulatory.
3. Modified nucleotides. Substituting modified uridine reduces innate immune activation and generally increases protein output in cells. Whether you want it depends on the application, since some experiments deliberately study that response. It changes the cost and should be specified explicitly.
4. Double-stranded RNA removal. Transcription generates double-stranded by-products that are potent innate immune triggers, and removing them is what separates good material from ordinary. Ask which purification is applied and whether residual double-stranded RNA is measured and reported per lot.
5. Formulation and delivery. Specify concentration, buffer and whether the material arrives naked or already formulated. Lipid nanoparticle formulation is a separate service with its own specification and its own analytics, and combining the two in one conversation obscures both.

The analytics to insist on

Integrity and size distribution, capping efficiency, poly-A tail length, residual double-stranded RNA, residual template DNA and endotoxin. A certificate reporting only concentration and a gel image is not enough to predict how the material will behave in cells.

Ask for the traces. As with every other category on this site, a summary figure without the underlying data cannot be assessed.

Handling what arrives

RNA is degraded by ubiquitous ribonuclease, so dedicated consumables, careful technique and aliquoting on arrival matter more here than for most reagents. Repeated freeze and thaw cycles cost integrity measurably.

Verify integrity on arrival rather than assuming the shipment travelled well, and keep a retained aliquot so a later question about the lot can be answered.

Common questions

Why does double-stranded RNA content matter?

Double-stranded by-products of transcription are potent innate immune triggers, so residual content largely determines how much response the material provokes in cells. Ask which purification is applied and whether residual content is measured per lot.

Co-transcriptional or enzymatic capping?

Co-transcriptional capping is one step; enzymatic capping is a second reaction with generally higher efficiency. Either way, ask what capping efficiency is measured and reported, since uncapped RNA is unproductive and immunostimulatory.

Should I specify modified nucleotides?

For most expression applications, modified uridine reduces innate activation and increases output. For experiments studying that response, unmodified material is the point. Specify it explicitly either way.

What analytics should accompany the mRNA?

Integrity and size distribution, capping efficiency, poly-A tail length, residual double-stranded RNA, residual template DNA and endotoxin, with the underlying traces rather than a summary.

Browse by service class

• Compare Gene synthesis on advertised prices